ログイン
Language:

WEKO3
  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

  1. 110 医歯薬学総合研究科 = Graduate School of Biomedical Sciences
  2. 110 学位論文 = dissertation
  3. 110 学位論文 = dissertation

Enhancing systemic lupus erythematosus treatment outcomes with an early initiation of belimumab: insights from a multicenter retrospective study within the first five years

http://hdl.handle.net/10069/0002003417
http://hdl.handle.net/10069/0002003417
e723b2fe-bda3-4764-8002-71d3db33847f
名前 / ファイル ライセンス アクション
KISYK53_Kojima.pdf KISYK53_Kojima.pdf (920 KB)
アイテムタイプ 学位論文 / Thesis or Dissertation(1)
公開日 2025-11-17
タイトル
タイトル Enhancing systemic lupus erythematosus treatment outcomes with an early initiation of belimumab: insights from a multicenter retrospective study within the first five years
言語 en
言語
言語 eng
キーワード
言語 en
主題Scheme Other
主題 Belimumab
キーワード
言語 en
主題Scheme Other
主題 Systemic lupus erythematosus
キーワード
言語 en
主題Scheme Other
主題 SELENA-SLEDAI
キーワード
言語 en
主題Scheme Other
主題 Disease duration
キーワード
言語 en
主題Scheme Other
主題 Early intervention
キーワード
言語 en
主題Scheme Other
主題 B cell therapy
資源タイプ
資源タイプ識別子 http://purl.org/coar/resource_type/c_db06
資源タイプ doctoral thesis
アクセス権
アクセス権 open access
アクセス権URI http://purl.org/coar/access_right/c_abf2
著者 小島, 加奈子

× 小島, 加奈子

ja 小島, 加奈子
Search repository
著者別名
姓名 Kojima, Kanako
言語 en
抄録
内容記述タイプ Abstract
内容記述 Background: The human monoclonal antibody belimumab (BEL) has emerged as a promising treatment for systemic lupus erythematosus (SLE), particularly for reducing the need for glucocorticoids and minimizing organ damage. The optimal timing of BEL initiation has been unclear; emerging evidence suggests that early intervention with BEL, particularly within the first 5 years of diagnosis, may yield better outcomes by modulating disease progression and reducing flare frequency. Understanding the relationship between disease duration and BEL efficacy is essential for the development of tailored strategies. Patients and methods: We analyzed patients with SLE treated at our hospital and associated facilities who were diagnosed according to the 1997 ACR or 2012 SLICC criteria and who began BEL treatment between December 2017 and August 2021. Patients who were followed for ≥ 12 months after BEL initiation were included. We investigated the changes in the patients' Safety of Estrogens in Lupus National Assessment–Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) scores at 3, 6, 9, and 12 months after the introduction of BEL, comparing patients with disease durations ≤ 5 years to those with > 5 years. A mixed-effects model was adjusted for the patients' ages, prednisolone dosages, initial SELENA-SLEDAI scores, Systemic Lupus International Collaborating Clinics (SLICC) damage index (SDI), hydroxychloroquine use, and lupus nephritis. Clinical manifestations including arthritis, skin lesions, and hematological abnormalities were monitored to assess the broader impacts of BEL. Results: One hundred eleven patients were initially registered; among them, 97 patients were included in the final analysis. The study population (mean age, 41 years; mean SELENA-SLEDAI, 7 points; 51% using hydroxychloroquine) included 19 patients with a ≤ 5-year SLE duration and 78 with SLE durations > 5 years. The baseline SELENA-SLEDAI scores were higher in the ≤ 5-year group (p = 0.047), indicating more active disease. Patients with ≤ 5 years of disease had significantly greater improvements in SELENA-SLEDAI scores at 6, 9, and 12 months (p < 0.05). Conclusions: These results highlight the importance of early BEL initiation in SLE, demonstrating that patients with shorter disease durations achieve more substantial improvements in disease activity with early BEL treatment. Our findings also reveal the potential benefits of early BEL intervention and suggest that incorporating the disease duration into treatment decisions may optimize patient outcomes.
言語 en
内容記述
内容記述タイプ Other
内容記述 長崎大学学位論文 学位記番号:共博(医歯薬)甲第53号 学位授与年月日:令和7年9月3日
言語 ja
内容記述
内容記述タイプ Other
内容記述 Author: Kanako Kojima, Kunihiro Ichinose, Masataka Umeda, Toshimasa Shimizu, Shuntaro Sato, Takahisa Suzuki, Yoshikazu Nakashima, Akitomo Okada, Yoshiro Horai, Keita Fujikawa, Toshiyuki Aramaki, Taiichiro Miyashita, Masako Furuyama, Naoki Matsuoka and Atsushi Kawakami
言語 en
内容記述
内容記述タイプ Other
内容記述 Citation: Arthritis Research & Therapy, 27, art. no. 116; 2025
言語 en
書誌情報 en : Arthritis Research & Therapy

巻 27, p. art. no. 116, 発行日 2025-09-03
ISSN
収録物識別子タイプ ISSN
収録物識別子 1478-6362
DOI
関連タイプ isIdenticalTo
識別子タイプ DOI
関連識別子 https://doi.org/10.1186/s13075-025-03581-0
権利
権利情報 © The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
言語 en
著者版フラグ
出版タイプ VoR
出版タイプResource http://purl.org/coar/version/c_970fb48d4fbd8a85
その他のタイトル
その他のタイトル ベリムマブの早期投与による全身性エリテマトーデス治療成果の向上：最初の5年間における多施設共同後方視的研究からの知見
言語 ja
出版者
出版者 BioMed Central Ltd
言語 en
関係URI
識別子タイプ HDL
関連識別子 http://hdl.handle.net/10069/0002003317
学位名
学位名 博士(医学)
言語 ja
学位授与機関
学位授与機関識別子Scheme kakenhi
学位授与機関識別子 17301
学位授与機関名 Nagasaki University (長崎大学)
学位授与年月日
学位授与年月日 2025-09-03
学位授与番号
学位授与番号 甲共医歯薬第53号
学位の種類
言語 ja
値 課程博士
引用
内容記述タイプ Other
内容記述 Nagasaki University (長崎大学), 博士(医学) (2025-09-03)
戻る
0
views
See details
Views

Versions

Ver.1 2025-11-17 02:46:17.783498
Show All versions

Share

Share
tweet

Cite as

Other

print

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR 2.0
  • OAI-PMH JPCOAR 1.0
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX
  • ZIP

コミュニティ

確認

確認

確認

Powered by WEKO3

Powered by WEKO3